SAN DIEGO, Feb. 14, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that it has entered into a licensing agreement granting Neopharm Group ("Neopharm" ...
SAN DIEGO, April 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it has filed a marketing application in Europe for Vitaros ® as a treatment ...
SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its ...
SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it ...
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about APRI -- Potential Market Size for Vitaros® for Erectile Dysfunction in ...
SAN DIEGO--(BUSINESS WIRE)-- Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq: APRI), announced today that Health Canada has granted marketing approval for Vitaros ® as a first-line therapy for ...
Apricus Biosciences, Inc. APRI, a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Ministry of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results